发明授权
- 专利标题: Percutaneous absorption preparation
- 专利标题(中): 经皮吸收制剂
-
申请号: US430384申请日: 1995-04-28
-
公开(公告)号: US5618555A公开(公告)日: 1997-04-08
- 发明人: Shoichi Tokuda , Kazuhisa Ninomiya , Yasuhiro Fukushima , Shigeyuki Watanabe , Mitsuru Ochiai , Mutsuo Okumura , Yuko Hosokawa
- 申请人: Shoichi Tokuda , Kazuhisa Ninomiya , Yasuhiro Fukushima , Shigeyuki Watanabe , Mitsuru Ochiai , Mutsuo Okumura , Yuko Hosokawa
- 申请人地址: JPX Osaka JPX Tokyo
- 专利权人: Itto Denko Corporation,Nikken Chemicals Co., Ltd.
- 当前专利权人: Itto Denko Corporation,Nikken Chemicals Co., Ltd.
- 当前专利权人地址: JPX Osaka JPX Tokyo
- 优先权: JPX6-094241 19940506
- 主分类号: A61K9/00
- IPC分类号: A61K9/00 ; A61K9/70 ; A61K31/485 ; A61K47/14 ; A61P25/04 ; A61F13/00
摘要:
A percutaneous absorption preparation which is excellent in the skin penetration of a non-narcotic analgesic buprenorphine and can sustain a high blood level in a stable state over a long period of time is provided. The percutaneous absorption preparation for administrating buprenorphine hydrochloride and/or buprenorphine, which comprises a support having on one surface thereof a plaster layer containing a pressure-sensitive adhesive, buprenorphine hydrochloride and/or buprenorphine, and a penetration enhancer, wherein the penetration enhancer comprises a combination of a monoglyceride of a fatty acid having 6 to 8 carbon atoms and isopropyl myristate, and the plaster layer contains at least 10% by weight of a monoglyceride off fatty acid having 6 to 8 carbon atoms and at least 5% by weight off isopropyl myristate, with the proviso that the content of the whole penetration enhancer ranges from 25 to 50% by weight. The combined use of the fatty acid monoglyceride and isopropyl myristate as a penetration enhancer synergistically elevates skin penetration of buprenorphine hydrochloride and/or buprenorphine.
公开/授权文献
- US4991621A Pressure regulator 公开/授权日:1991-02-12
信息查询